PMCB (PharmaCyte Biotech) Total Assets: $55.87 Mil (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.75
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Total Assets?

PharmaCyte Biotech PMCB +1.44% 32 Total Assets is $55.87 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

PharmaCyte Biotech's Total Assets for the quarter that ended in Jan. 2026 was $55.87 Mil.

During the past 12 months, PharmaCyte Biotech's average Total Assets Growth Rate was 30.50% per year. During the past 3 years, the average Total Assets Growth Rate was 96.50% per year. During the past 5 years, the average Total Assets Growth Rate was 40.80% per year. During the past 10 years, the average Total Assets Growth Rate was 10.90% per year.

During the past 13 years, PharmaCyte Biotech's highest 3-Year average Total Assets Growth Rate was 258.90%. The lowest was -42.10%. And the median was 0.40%.

Total Assets is connected with ROA %. PharmaCyte Biotech's annualized ROA % for the quarter that ended in Jan. 2026 was 5.34%. Total Assets is also linked to Revenue through Asset Turnover. PharmaCyte Biotech's Asset Turnover for the quarter that ended in Jan. 2026 was 0.00.

PharmaCyte Biotech  (NAS:PMCB) Total Assets Explanation

Total Assets is connected with ROA %.

PharmaCyte Biotech's annualized ROA % for the quarter that ended in Jan. 2026 is

ROA %=Net Income (Q: Jan. 2026 )/( (Total Assets (Q: Oct. 2025 )+Total Assets (Q: Jan. 2026 ))/ count )
=2.988/( (55.976+55.874)/ 2 )
=2.988/55.925
=5.34 %

Note: The Net Income data used here is four times the quarterly (Jan. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

PharmaCyte Biotech's Asset Turnover for the quarter that ended in Jan. 2026 is

Asset Turnover
=Revenue (Q: Jan. 2026 )/( (Total Assets (Q: Oct. 2025 )+Total Assets (Q: Jan. 2026 ))/ count )
=0/( (55.976+55.874)/ 2 )
=0/55.925
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

PharmaCyte Biotech Total Assets Related Terms

PharmaCyte Biotech Total Assets Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Total Assets Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.40 90.62 73.28 59.90 55.17

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.83 55.17 45.11 55.98 55.87
PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

PharmaCyte Biotech's Total Assets for the fiscal year that ended in Apr. 2025 is calculated as

Total Assets=Total Equity (A: Apr. 2025 )+Total Liabilities (A: Apr. 2025 )
=51.891+3.277
=55.17

PharmaCyte Biotech's Total Assets for the quarter that ended in Jan. 2026 is calculated as

Total Assets=Total Equity (Q: Jan. 2026 )+Total Liabilities (Q: Jan. 2026 )
=39.402+16.471
=55.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $55.87 Mil mean?
PharmaCyte Biotech (PMCB) has a Total Assets of $55.87 Mil as of Jan. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Total Assets too high?
PharmaCyte Biotech's current Total Assets is $55.87 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Total Assets compare to IMNN and ACXP?
PharmaCyte Biotech's Total Assets of $55.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Total Assets is $55.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Total Assets of $55.87 Mil. The current Total Assets is $55.87 Mil. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Total Assets is $55.87 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.75
Price